Inovio Pharmaceuticals, Inc. (INO)
0.8971
+0.06
(+6.94%)
USD |
NASDAQ |
Oct 23, 16:00
0.8929
0.00 (0.00%)
After-Hours: 20:00
Inovio Pharmaceuticals Enterprise Value : 45.20M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 45.20M |
| October 22, 2026 | 40.40M |
| October 21, 2026 | 36.81M |
| October 20, 2026 | 54.49M |
| October 19, 2026 | 53.67M |
| October 16, 2026 | 52.85M |
| October 15, 2026 | 56.96M |
| October 14, 2026 | 52.52M |
| October 13, 2026 | 53.52M |
| October 12, 2026 | 62.32M |
| October 09, 2026 | 66.02M |
| October 08, 2026 | 61.08M |
| October 07, 2026 | 66.43M |
| October 06, 2026 | 64.37M |
| October 05, 2026 | 66.02M |
| October 02, 2026 | 66.84M |
| October 01, 2026 | 70.96M |
| September 30, 2026 | 71.79M |
| September 29, 2026 | 62.73M |
| September 28, 2026 | 67.67M |
| September 25, 2026 | 68.49M |
| September 24, 2026 | 70.96M |
| September 23, 2026 | 74.26M |
| September 22, 2026 | 77.55M |
| September 21, 2026 | 73.43M |
| Date | Value |
|---|---|
| September 18, 2026 | 73.43M |
| September 17, 2026 | 70.96M |
| September 16, 2026 | 66.02M |
| September 15, 2026 | 66.84M |
| September 14, 2026 | 68.49M |
| September 11, 2026 | 74.26M |
| September 10, 2026 | 76.73M |
| September 09, 2026 | 80.02M |
| September 08, 2026 | 88.25M |
| September 04, 2026 | 89.08M |
| September 03, 2026 | 83.31M |
| September 02, 2026 | 83.31M |
| September 01, 2026 | 80.84M |
| August 31, 2026 | 75.90M |
| August 28, 2026 | 77.55M |
| August 27, 2026 | 75.08M |
| August 26, 2026 | 78.37M |
| August 25, 2026 | 77.55M |
| August 24, 2026 | 74.26M |
| August 21, 2026 | 68.49M |
| August 20, 2026 | 70.96M |
| August 19, 2026 | 78.37M |
| August 18, 2026 | 70.14M |
| August 17, 2026 | 66.02M |
| August 14, 2026 | 61.08M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Nektar Therapeutics | 721.90M |
| Ironwood Pharmaceuticals, Inc. | 889.47M |
| Fortress Biotech, Inc. | -37.02M |
| Tonix Pharmaceuticals Holding Corp. | -88.14M |
| Kura Oncology, Inc. | 360.28M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.012M |
| Total Expenses (Quarterly) | 6.012M |
| EPS Diluted (Quarterly) | -0.0737 |
| Earnings Yield | -131.1% |
| Normalized Earnings Yield | -139.79 |